Authors: Yee, Karen WL; O'Brien, Susan M

Source: Expert Opinion on Emerging Drugs, Volume 11, Number 1, 1 March 2006 , pp. 167-189(23)

Publisher: Informa Healthcare

Abstract:

Although the philosophy of management of patients with chronic lymphocytic leukaemia (CLL) has been altered with the advent of fludarabine-based therapies, impact on long-term survival is unclear and a significant proportion of patients will develop resistance to fludarabine. Similar to other haematological malignancies, a potential for `cure' is likely to be achieved only if `high-quality' complete remissions (CRs) are achieved. Treatment options for patients who develop resistance to fludarabine continue to be limited, with only a proportion obtaining a response (usually not CRs) with salvage therapies. This review summarises novel therapies that are being evaluated in patients with CLL, specifically those targeting the antiapoptotic Bcl-2 family of proteins and receptors (e.g., CD40, CD80, HLA-DR) involved in mediating survival signals from the microenvironment.

Keywords: 1D09C3; apolizumab; BH3 mimetics; CHIR-12.12; chronic lymphocytic leukaemia; epratuzumab; galiximab; lumiliximab; oblimersen sodium

Document Type: Review article

DOI: http://dx.doi.org/10.1517/14728214.11.1.167

Publication date: 2006-03-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Yee, Karen WL ;  O'Brien, Susan M

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers